Tryptase as a marker of severity of aortic valve stenosis

Laura M Losappio, Corrado Mirone, Michel Chevallard, Laura Farioli, Fabrizio De Luca, Elide A Pastorello, Laura M Losappio, Corrado Mirone, Michel Chevallard, Laura Farioli, Fabrizio De Luca, Elide A Pastorello

Abstract

Background: Severe aortic valve stenosis is one of the most common cause of mortality in adult patients affected with metabolic syndrome, a condition associated with an active inflammatory process involving also mast cells and their mediators, in particular tryptase. The aim of this study was to characterize the possible long-term prognostic role of tryptase in severe aortic valve stenosis.

Case presentation: The baseline serum tryptase was measured in 5 consecutive patients admitted to our Hospital to undergo aortic valve replacement for severe acquired stenosis. Within 2 years after, the patients were evaluated for the occurrence of major cardiovascular events (MACE). The tryptase measurements were higher in patients experiencing MACE (10.9, 11.7 and 9.32 ng/ml) than in non-MACE ones (5.69 and 5.58 ng/ml).

Conclusions: In patients affected with severe aortic stenosis, baseline serum tryptase may predict occurence of MACE. Further studies are needed to demonstrate the long-term prognostic role of this biomarker.

Keywords: Aortic valve stenosis; Biomarker; Tryptase.

References

    1. Pagé A, Dumesnil JG, Clavel MA, Chan KL, Teo KK, Tam JW, Mathieu P, Després JP, Pibarot P, ASTRONOMER Investigators Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin) J Am Coll Cardiol. 2010;55(17):1867–1874. doi: 10.1016/j.jacc.2009.11.083.
    1. Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodés-Cabau J, Bertrand OF, Poirier P. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28(6):1039–1049. doi: 10.1161/ATVBAHA.107.159228.
    1. Olszowska M. Pathogenesis and pathophysiology of aortic valve stenosis in adults. Pol Arch Med Wewn. 2011;121(11):409–413.
    1. Townsend CM, et al. Sabiston textbook of surgery. 18. New York: Saunders; 2008. pp. 1841–1844.
    1. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM, 3rd, Thomas JD, American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(22):2438–2488. doi: 10.1016/j.jacc.2014.02.537.
    1. Dahou A, Clavel MA, Capoulade R, O’Connor K, Ribeiro HB, Côté N, Le Ven F, Rodés-Cabau J, Dumesnil JG, Mathieu P, Pibarot P. B-type natriuretic peptide and high-sensitivity cardiac troponin for risk stratification in low-flow, low-gradient aortic stenosis: a substudy of the TOPAS study. JACC Cardiovasc Imaging. 2017
    1. Steiner I, Krbal L, Rozkoš T, Harrer J, Laco J. Calcific aortic valve stenosis: immunohistochemical analysis of inflammatory infiltrate. Pathol Res Pract. 2012;208(4):231–234. doi: 10.1016/j.prp.2012.02.009.
    1. Wypasek E, Natorska J, Grudzień G, Filip G, Sadowski J, Undas A. Mast cells in human stenotic aortic valves are associated with the severity of stenosis. Inflammation. 2013;36:449–456. doi: 10.1007/s10753-012-9565-z.
    1. Valent P. Mast cell activation syndromes: definition and classification. Allergy. 2013;68(4):417–424. doi: 10.1111/all.12126.
    1. Searle J, Danne O, Müller C, Mockel M. Biomarkers in acute coronary syndrome and percutaneous coronary intervention. Minerva Cardioangiol. 2011;59:203–223.
    1. Kounis NG, Tsigkas G, Almpanis G, Kounis GN, Mazarakis A, Hahalis G. Tryptase levels in coronary syndrome and in hypersensitivity episodes: a common path was towards Kounis syndrome. Atherosclerosis. 2011;219(1):28–29. doi: 10.1016/j.atherosclerosis.2011.07.101.
    1. Morici N, Farioli L, Losappio LM, Colombo G, Nichelatti M, Preziosi D, Micarelli G, Oliva F, Giannattasio C, Klugmann S, Pastorello EA. Mast cells and acute coronary syndromes: relationship between serum tryptase clinical outcomes and severity of coronary artery disease. Open Heart. 2016;3(2):e000472. doi: 10.1136/openhrt-2016-000472.
    1. Pastorello EA, Farioli L, Losappio LM, Morici N, Di Biase M, Nichelatti M, Schroeder JW, Balossi L, Klugmann S. Serum tryptase detected during acute coronary syndrome is significantly related to the development of major adverse cardiovascular events after 2 years. Clin Mol Allergy. 2015;13(1):14. doi: 10.1186/s12948-015-0013-0.
    1. Helske S, Lindstedt KA, Laine M, Mäyränpää M, Werkkala K, Lommi J, Turto H, Kupari M, Kovanen PT. Induction of local Angiotensin II producing systems in stenotic aortic valves. J Am Coll Cardiol. 2004;44(9):1859–1866. doi: 10.1016/j.jacc.2004.07.054.
    1. Syva¨ranta S, Helske S, Laine M, Lappalainen J, Kupari M, Ma¨yra¨npa¨a¨ MI, Lindstedt KA, Kovanen PT. Vascular endothelial growth factor-secreting mast cells and myofibroblasts: a novel self-perpetuating angiogenic pathway in aortic valve stenosis. Arterioscler Thromb Vasc Biol. 2010;30(6):1220–1227. doi: 10.1161/ATVBAHA.109.198267.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel